Clinical trials
Bipolar Disorder I or II clinical trials
Below are recruiting bipolar disorder i or ii clinical trials, each written for real people, not researchers. We’re tracking 2,385 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT05438563Recruiting
MRI-guided prostate cancer ablation with ultrasound from the urethra
This trial tests a newer way to treat certain low- to intermediate-risk prostate cancers using MRI guidance and an ultrasound probe placed through the urethra. It aims to destroy the tumor while using imaging to help target it more precisely.
Rochester, MinnesotaAges 45–80 - NCT05977439Recruiting
Brain training for depression recovery
This study uses brain imaging and stimulation to help people with depression learn how to regulate their emotions better. It aims to find out if targeting specific brain networks can improve symptoms.
Charleston, South CarolinaAges 18–65 - NCT04798690Recruiting
Long-term growth injections for short children
This trial studies the long-term safety and effectiveness of Growtropin®-II, a growth hormone–type injection, in children who are short due to certain causes. It may help your child’s growth over time, while also closely tracking side effects.
Seoul, Seodaemun-guAges 2 years+ - NCT07253142RecruitingPhase 2
Study of HLX43 with Serplulimab for advanced lung cancer
This trial tests a new combination of two drugs for people with advanced lung cancer that has worsened after previous treatments like chemotherapy or immunotherapy. The goal is to see if this approach can help shrink tumors or slow the disease.
Hefei, AnhuiAges 18–75 - NCT05709782RecruitingPhase 2
MR-guided targeted radiation for limited-spine spinal metastasis
This Phase 2 study tests an MRI-guided radiation machine (an MR LINAC) to deliver very focused treatment to spine tumors. It may help by improving accuracy while treating up to a small number of spine levels affected by cancer.
Houston, TexasAges 18 years+ - NCT06471738RecruitingPhase 2
Targeted drug combo for untreated follicular lymphoma
This trial tests a combination of three targeted drugs (zanubrutinib, rituximab, and venetoclax) for people with untreated follicular lymphoma. The goal is to see if this combination works better than standard treatments and has manageable side effects.
BeijingAges 18 years+ - NCT07691749Recruiting
Psychobiotics plus antidepressants for Major Depression
This study tests whether adding psychobiotics (special probiotics for mental health) to your current antidepressant helps treat major depression better than the antidepressant alone. It may be an option if you have moderate to severe depression and are on a stable antidepressant dose.
Lahore, Punjab ProvinceAges 18–60 - NCT04479696Recruiting
Video coaching to ease anxiety during brain tumor radiation
This study tests a personalized video meant to reduce stress and anxiety for people getting radiation for brain tumors, and for their caregivers. You and your caregiver would complete short questionnaires before and after using the video support.
Houston, TexasAges 18 years+ - NCT05172245RecruitingPhase 1
Testing a new drug added to chemoradiation for head and neck cancer
This study tests whether adding a new targeted drug called ipatasertib to standard chemoradiation can improve treatment for people with locally advanced head and neck cancer. Ipatasertib may help block a protein that helps cancer grow, possibly making the standard therapy more effective.
Tampa, FloridaAges 18 years+ - NCT06916585RecruitingPhase 2
Testing AS1501 for acute-on-chronic liver failure
This trial tests a new drug called AS1501 for people with acute-on-chronic liver failure (a sudden worsening of chronic liver disease). It aims to see if the drug can help improve liver function and reduce the need for a liver transplant. You may be eligible if you are in the early or middle stage of this condition and have a specific blood marker (high TRAIL level).
Shenzhen, GuangdongAges 18–75 - NCT06067269RecruitingPhase 2
Hormone therapy and precise radiation for intermediate-risk prostate cancer
This trial tests whether giving a short course of hormone therapy (apalutamide) along with targeted, high-dose radiation (SBRT) is safe and effective for men with a specific type of intermediate-risk prostate cancer. You may benefit if you fit the exact risk and test criteria.
Los Angeles, CaliforniaAges 18 years+ - NCT05535192Recruiting
Telehealth strength exercise to help older women during breast cancer chemo
This study tests whether a supervised at-home (telehealth) strength exercise program can help older women stay strong and keep their chemotherapy on schedule. It’s meant for women who are starting chemotherapy for breast cancer with the goal of cure.
Boston, MassachusettsAges 65 years+ - NCT07704060Recruiting
Helping male caregivers of older adults
This study tests an intervention designed to support men who care for an older adult (65+). It uses a smartphone app to help with caregiving tasks.
Atlanta, GeorgiaAges 18 years+ - NCT05023018RecruitingPhase 2
NEO100 for recurrent or progressive high-grade meningioma
This trial studies NEO100, a treatment for adults and children (age 12+) with Grade II or III meningioma that has come back or kept growing after surgery and radiation. It may help shrink tumors or slow growth when standard options have not worked well enough.
Los Angeles, CaliforniaAges 12 years+ - NCT06388967Recruiting
Pancreatic cancer detection study
This study is looking at blood or tissue samples from people with pancreatic cancer and from those without it. The goal is to find ways to detect the cancer earlier.
Phoenix, ArizonaAges 18 years+ - NCT07704177RecruitingPhase 2
A study of trastuzumab rezetecan plus two other drugs for advanced bile duct cancer
This trial tests a combination of three drugs (trastuzumab rezetecan, adebrelimab, and lenvatinib) for people with advanced bile duct or gallbladder cancer that has HER2 protein on its cells. The goal is to see if this combination can help shrink tumors or slow the cancer's growth.
Beijing, Beijing MunicipalityAges 18–80 - NCT03618550RecruitingPhase 2
Pembrolizumab plus chemotherapy for relapsed Hodgkin lymphoma
This study tests a combination of the immunotherapy drug pembrolizumab with a chemotherapy regimen called GVD for patients whose Hodgkin's lymphoma has not responded or has returned after initial treatment. The goal is to see if this combination works better than standard approaches.
Duarte, CaliforniaAges 18 years+ - NCT07704138Recruiting
Testing process-based therapy for depression and anxiety
This trial tests a type of talking therapy called process-based therapy to see how well it works in everyday care. It focuses on treating depression or anxiety and helps therapists learn how to make better treatment decisions.
Frankfurt am Main, HesseAges 18–65 - NCT07258563Recruiting
Can a special diet prevent taste changes from chemo?
This study looks at whether a special diet can help prevent taste changes during chemotherapy. It is for people with certain cancers who are about to start treatment.
AmsterdamAges 18–70 - NCT05053971RecruitingPhase 1/Phase 2
Entinostat plus ZEN003694 for advanced solid tumors
This Phase 1/2 study tests a new combination anti-cancer treatment (entinostat plus ZEN003694) in people with advanced solid tumors that can’t be controlled with standard care. It aims to find a safe dose and see whether the treatment can shrink tumors or control the disease.
New Haven, ConnecticutAges 18 years+ - NCT03050268Recruiting
Study of childhood cancer risk in families
This study looks at inherited (family) risk for childhood cancers, including families with early cancers or known cancer risk conditions. It may help researchers understand why some children get cancer and improve future risk detection and care.
Memphis, TennesseeAges Any age - NCT03180268RecruitingPhase 3
Watch or radiate after surgery for grade II meningioma
This trial studies whether people with a grade II meningioma that has been completely removed by surgery should be monitored only or treated with radiation. It may help reduce the risk of the tumor coming back while balancing radiation side effects.
Birmingham, AlabamaAges 18 years+ - NCT03326947RecruitingPhase 2
Stathmin test to guide chemotherapy for oral cancer
This Phase 2 trial uses a lab test called “Stathmin” to help predict who may benefit from a specific chemotherapy plan for squamous cell carcinoma of the mouth. It aims to improve treatment choice by linking Stathmin levels to how well chemotherapy works.
Shanghai, Shanghai MunicipalityAges 18–75 - NCT03379909RecruitingPhase 2
Metformin taken by mouth for early bladder cancer
This trial studies whether a diabetes medicine called metformin can help prevent or control non-muscle-invasive bladder cancer inside the bladder. You would take it by mouth, and the study checks safety and whether it works.
Nijmegen, GelderlandAges 18 years+
Hear when a new Bipolar Disorder I or II trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for bipolar disorder i or ii?
- Yes. Clin2 currently lists 2,385 recruiting bipolar disorder i or ii studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a bipolar disorder i or ii trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a bipolar disorder i or ii trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.